Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

National University Hospital Singapore Operates on Asia's 1st TRAM Flap Patient Using TIGR® Matrix Surgical Mesh, the World's 1st Long-Term Resorbable Mesh

October 25, 2010 11:36 am | by Bio-Medicine.Org | News | Comments

SINGAPORE, Oct. 25 /- Singapore company Novus Scientific Pte. Ltd today announced that the National University Hospital (NUH), Singapore has operated on the first patient in its groundbreaking study: Abdominal Wall Closure After Lipectomy, TRAM /DIEP Flap - Comparison of TIGR® Matrix...

PAREXEL International to Present at Oppenheimer Healthcare Conference and Morningstar Annual Stocks Forum

October 25, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

BOSTON, Oct. 25 /- PAREXEL International Corporation (Nasdaq: PRXL ) announced today it will be presenting at the Oppenheimer Healthcare Conference in New York.  James Winschel, Senior Vice President and Chief Financial Officer will be making a presentation on PAREXEL at 2:45 p.m....

PolyOne GLS Selected as Healthcare Industry Marketing Specialist for Santoprene™ TPV Medical Grades

October 25, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

CLEVELAND, Oct. 25 /- PolyOne Corporation announced that PolyOne GLS Thermoplastic Elastomers has been chosen by ExxonMobil Chemical Company to be its primary marketing specialist for thermoplastic vulcanizate (TPV) medical products made using ExxonMobil Chemical's Santoprene™ TPV....

Advertisement

Roper Industries Announces Record Third Quarter Results

October 25, 2010 4:35 am | by Bio-Medicine.Org | News | Comments

SARASOTA, Fla., Oct. 25 /- Roper Industries, Inc. (NYSE: ROP ) reported record results for its third quarter ended September 30, 2010.   Net earnings for the third quarter were $84 million, a 49% increase over the third quarter of 2009, and diluted earnings per share (DEPS) were...

Intercell Reports Positive Results From Its Phase II Pseudomonas Aeruginosa Investigational Vaccine Study for Certain Hospital-Acquired Infections

October 25, 2010 12:33 am | by Bio-Medicine.Org | News | Comments

VIENNA, Oct. 25 /- Intercell AG (VSE: ICLL) today announced results from a Phase II clinical trial involving the company's investigational nosocomial vaccine candidate (IC43) against infections with the bacterium Pseudomonas aeruginosa , a leading cause of hospital-acquired infections...

NCPA Announces Kathleen Jaeger as CEO

October 24, 2010 10:34 am | by Bio-Medicine.Org | News | Comments

ALEXANDRIA, Va., Oct. 24 /PRNewswire-USNewswire/ -- The National Community Pharmacists Association (NCPA) today announced the appointment of Kathleen Jaeger as Executive Vice President and CEO, heralding her as an ideal choice to build on the association's recent accomplishments and lead...

Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA

October 23, 2010 9:31 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 23 /- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America...

Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS ) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the...

Advertisement

Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

BELGRADE, Mont., Oct. 22 /- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI ) ("Bacterin"), announced today that it has scheduled a conference call for Monday, November 15, 2010 at 10:00 a.m. (ET) to discuss the Company's financial results for its third quarter 2010, which...

AdvaMed 2010 Sets New Attendance Record: More than 1,700 Device and Diagnostics Leaders from Across the Country and Around the World Came to Washington, D.C.

October 22, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- More than 1,700 medical device and diagnostics leaders from more than 360 companies – representing 24 countries and 33 states – attended the fourth annual industry gathering, AdvaMed 2010: The MedTech Conference this week in...

CareFusion Will Host an Earnings Conference Call on Nov. 2 to Discuss the Results for the First Quarter Fiscal 2011

October 21, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 21 /- CareFusion (NYSE: CFN ), a leading, global medical device company, today announced plans to release first quarter fiscal 2011 results on Tuesday, Nov. 2 before the start of trading on the New York Stock Exchange. (Logo:  ...

Span-America Announces Fourth Quarter and Fiscal Year-End 2010 Conference Call on the Internet

October 21, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

GREENVILLE, S.C., Oct. 21 /- Span-America Medical Systems, Inc. (Nasdaq:  SPAN) will provide an online, real-time webcast and rebroadcast of its conference call on Tuesday, November 2, 2010, covering results for the fourth quarter and fiscal year-end 2010, which will be released...

VirtualScopics Schedules Third Quarter 2010 Earnings Announcement

October 21, 2010 9:32 am | by Bio-Medicine.Org | News | Comments

ROCHESTER, N.Y., Oct. 21 /- VirtualScopics, Inc. (Nasdaq: VSCP ), a leading provider of quantitative imaging for clinical trials, announced today that before the market opens on Thursday, November 11, 2010 it will release its third quarter 2010 financial results. The company will host a...

Advertisement

Algeta and Lumiphore Announce Global Agreement for the Development of Targeted Alpha-Pharmaceutical Therapeutics

October 21, 2010 5:34 am | by Bio-Medicine.Org | News | Comments

RICHMOND, Calif., Oct. 21 /- Lumiphore Inc., a biotechnology leader in new proprietary bifunctional metal-chelation technology for use in high-value imaging, diagnostics, and therapeutics and Algeta ASA (OSE:ALGETA), the cancer therapeutics company, announced that they have signed a...

IDEV Technologies Launches Additional Products in Europe

October 21, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

WEBSTER, Texas, Oct. 21 /- IDEV Technologies, Incorporated (IDEV), an innovative leader in the development and commercialization of minimally invasive medical technologies, today announced another step in the implementation of its strategy to expand its product line for treating patients...

Danaher Reports Record Third Quarter 2010 Results

October 21, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

WASHINGTON, Oct. 21 /- Danaher Corporation (NYSE: DHR ) announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a...

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

October 21, 2010 1:32 am | by Bio-Medicine.Org | News | Comments

LONDON, Oct. 21 /- Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational integrase inhibitor, S/GSK1349572 ('572). The Phase III clinical programme, which began this month, includes two studies...

Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C

October 21, 2010 1:31 am | by Bio-Medicine.Org | News | Comments

VIENNA, Oct. 21 /- Intercell AG (VSE; "ICLL") and Romark Laboratories L.C. today announced plans to commence clinical trials of Intercell's investigational therapeutic Hepatitis C virus (HCV) vaccine, IC41, in combination with Romark's antiviral drug, nitazoxanide, during the first half...

Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis)

October 20, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to... -- MUMBAI, India, October 20, 2010 /-

Genoptix Ranked 41st Fastest-Growing Company in North America on Deloitte's 2010 Technology Fast 500™

October 20, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Oct. 20 /- Genoptix, Inc. (Nasdaq: GXDX ), a specialized laboratory services provider, today announced that it ranked number 41 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean...

Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010

October 20, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

MADISON, N.J., Oct. 20 /- Quest Diagnostics Incorporated (NYSE: DGX ), the world's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2010, income from continuing operations increased to $198 million, or $1.13 per...

Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010

October 20, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

MINNEAPOLIS, Oct. 20 /- Uroplasty, Inc. (Nasdaq: UPI ) announced today that it will release financial results for the second quarter ended September 30, 2010, at the market close on Wednesday, October 27, 2010.  The Company will host a conference call to discuss these results on...

BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors

October 19, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

SEOUL, South Korea, Oct. 19 /- BioMolecular Therapeutics, Inc. (BMT, Inc.), a new Seoul-based RNAi therapeutics company with a proprietary technology designed to reduce significantly deleterious side effects triggered by conventional siRNA, announced that it has launched its global...

LifePort Inc. Signs Two Agreements Launching Company Into Mission-Specific Seating

October 19, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

ATLANTA, Oct. 19 /- NBAA Trade Show -- LifePort Inc. today announced the signing of two agreements that launch the company into customized mission-specific seating. LifePort is a Sikorsky Aerospace Services (SAS) company – the aftermarket division of Sikorsky Aircraft Corp., a...

Celsion Announces ThermoDox's Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium

October 19, 2010 10:33 am | by Bio-Medicine.Org | News | Comments

COLUMBIA, Md., Oct. 19 /- Celsion Corporation (Nasdaq: CLSN ) announced today that two abstracts on the ThermoDox® High Intensity Focused Ultrasound (HIFU) development program have been delivered via oral presentation at the MR-guided Focused Ultrasound 2010 2nd International...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading